- The Maharashtra Food and Drug Administration has barred the sale and distribution of certain medicines manufactured by Cadila Pharmaceuticals Ltd over branding similarities despite differing active pharmaceutical ingredients. - Regulators seized stock worth approximately Rs 2.45 crore across the state as part of the enforcement action. - The action targets potential medication errors arising from look-alike branding of products containing different active pharmaceutical ingredients. - The move underscores regulatory scrutiny of drug naming and packaging to safeguard patient safety in pharmaceutical distribution.

Jul 12, 2026

返回机构列表

Cadila Pharmaceuticals Ltd.

概览

试验阶段分布

试验状态分布

相关临床试验

该机构主办的试验（20）

To observe safety of Vasograin (a combination of Ergotamine, Paracetamol, Prochlorperazine, and Caffeine) for treating migraines in adults: an open study where all participants receive the same treatment.

Study of Inj. SepsivacÂ® in bacterial sepsis

A Post Marketing Surveillance of inj. mycobacterium w in patients with Gram Negative Sepsis

Study to evaluate the effects of new drug of diabetes mellitus in healthy volunteers.

Study of GCSF in Patients on Myelosuppresive Therapy for Non-Myeloid Malignancies.

Comparative Assessment of Tolerability, Efficacy and Safety of Combination of Compound CDRI 80/574 and Atorvastatin versus Atorvastatin in subjects with Hyperlipidemia

Study of Mycobacterium w in BCG refractory Superficial Transitional Cell Carcinoma of Bladder

Clinical trial of Mycobacterium w in Combination withPaclitaxel and Cisplatin in Advanced non small cell lung cancer patients.

药物批准

按机构分类的批准

近期批准

资讯

Maharashtra FDA Bars Sale of Two Cadila Drugs Over Brand Confusion, Seizes Rs 2.45 Crore Stock